Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Solid Tumors 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × glasdegib × Clear all
NCT02038777 2025-02-26

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Pfizer

Phase 1 Completed
48 enrolled 85 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00953758 2024-04-25

A Study Of PF-04449913 In Select Hematologic Malignancies

Pfizer

Phase 1 Completed
47 enrolled 45 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡